Clinical Pediatric Emergency Medicine
Volume 9, Issue 4 , Pages 258-263 , December 2008

Empiric Antibiotics for the Complex Febrile Child: When, Why, and What to Use

  • Yiannis L. Katsogridakis, MD, MPH

      Affiliations

    • Corresponding Author InformationReprint requests and correspondence: Yiannis L. Katsogridakis, MD, MPH, Division of Pediatric Emergency Medicine, Children's Memorial Hospital, 2300 Children's Plaza, Box 62, Chicago, IL 60614-3394.
    • ,
  • Kristine L. Cieslak, MD

References 

  1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  2. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551–573
  3. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis. 2004;39(Suppl 1):S44–S48
  4. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323–1332
  5. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103:1103–1113
  6. Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med. 1984;310:553–559
  7. Piatt JH, Garton HJ. Clinical diagnosis of ventriculoperitoneal shunt failure among children with hydrocephalus. Pediatr Emerg Care. 2008;24:201–210
  8. Ronan A, Hogg GG, Klug GL. Cerebrospinal fluid shunt infections in children. Pediatr Infect Dis J. 1995;14:782–786
  9. Forward KR, Fewer HD, Stiver HG. Cerebrospinal fluid shunt infections, a review of 35 infections in 32 patients. J Neurosurg. 1983;59:389–394
  10. Kontny U, Hofling B, Gutjahr P, et al. CSF shunt infections in children. Infection. 1993;21:89–92
  11. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–1284
  12. Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis. 1975;131:543–552
  13. Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J. 2002;21:632–636
  14. Cook AM, Ramsey CN, Martin CA, et al. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg. 2005;41:102–104
  15. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Cur Opin Pulm Med. 2006;12:440–444
  16. Cystic Fibrosis Foundation . Patient registry annual data report 2006. Bethesda, Maryland: Cystic Fibrosis Foundation; 2006;
  17. Blumer JL, Saiman L, Konstan MW, et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest. 2005;128:2336–2346
  18. Diamanti A, Basso MS, Castro M, et al. Prevalence of life-threatening complications in pediatric patients affected by intestinal failure. Transplant Proceed. 2007;39:1632–1633
  19. Onder AM, Kato T, Simon N, et al. Prevention of catheter-related bacteremia in pediatric intestinal transplantation/short gut syndrome children with long-term central venous catheters. Pediatr Transplant. 2007;11:87–93
  20. Piedra PA, Dryja DM, LaScolea LJ. Incidence of catheter-associated gram-negative bacteremia in children with short bowel syndrome. J Clin Microbiol. 1989;27:1317–1319
  21. Terra RM, Plopper C, Waitzberg DL, et al. Remaining small bowel length: association with catheter sepsis in patients receiving home total parenteral nutrition: evidence of bacterial translocation. World J Surg. 2000;24:1537–1541
  22. U.S. Food and Drug Administration. Center for Drug Evaluation and Research . U.S. Department of Health and Human Services. Early communication about an ongoing safety review, cefepime. (marketed as Maxipime). Available at: http://www.fda.gov/cder/drug/early_comm/cefepime.htmAccessed 07-20-2008
  23. U.S. Food and Drug Administration . Center for Drug Evaluation and Research. U.S. Department of Health and Human Services. Update of safety review, follow-up to the November 14, 2007, communication about the ongoing safety review of cefepime (marketed as Maxipime). Available at: http://www.fda.gov/cder/drug/early_comm/cefepime_update_200805.htmAccessed 07-20-2008
  24. U.S. Food and Drug Administration . Center for Drug Evaluation and Research. U.S. Department of Health and Human Services. Linezolid (marketed as Zyvox) Information. Available at: http://www.fda.gov/cder/drug/infopage/linezolid/default.htmAccessed 07-20-2008

PII: S1522-8401(08)00070-0

doi: 10.1016/j.cpem.2008.09.006

Clinical Pediatric Emergency Medicine
Volume 9, Issue 4 , Pages 258-263 , December 2008

Article Tools